Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Suspended  
  • Page 1 ·  Next »

NCT ID: NCT04762771 Suspended - Covid19 Clinical Trials

Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19)

Start date: December 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label unblinded, randomized study to treat hospitalized covid-19 patients with colchicine plus current care (per institution treating physicians) vs. current care per institution treating physicians alone (the control arm)

NCT ID: NCT04750759 Suspended - Covid19 Clinical Trials

Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat

Start date: February 3, 2021
Phase: Phase 2
Study type: Interventional

Niclosamide (2000 mg QD) and Camostate (600 mg QID) are expected to be safe and well-tolerated as a combination therapy and to show clinically beneficial for COVID-19 patients.

NCT ID: NCT04738136 Suspended - Covid19 Clinical Trials

Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia

Start date: September 15, 2021
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, controlled, Phase II proof of concept study to evaluate the safety, tolerability and efficacy of S-1226 in which hospitalized subjects (n≤30) with moderate severity COVID-19 Bronchiolitis/Pneumonia will be enrolled. The safety and tolerability of S-1226 composed of PFOB with ascending doses of carbon dioxide (4%, 8%, and 12% CO2) administered twice daily will be assessed subjects in hospitalized subjects with moderate severity COVID-19 Bronchiolitis/Pneumonia.

NCT ID: NCT04711863 Suspended - Clinical trials for Coronavirus Infection

Fluvoxamine for Adults With Mild to Moderate COVID-19

Start date: January 16, 2021
Phase: Phase 2
Study type: Interventional

This clinical trial aims to determine if fluvoxamine, a selective serotonin reuptake inhibitor with high affinity for the sigma-1 receptor, can be used in mild to moderate COVID-19 to prevent the progression to severe COVID-19. Fluvoxamine is an anti-depressant drug approved by the FDA for the treatment of obsessive-compulsive disorder and has a potential for immune modulation as a sigma-1 receptor agonist. The investigational use of fluvoxamine for the treatment of COVID-19 is approved by the South Korean Ministry of Food and Drug Safety. This study is performed fully-remotely at COVID-19 community treatment centers, temporary facilities in Seoul, Korea, to accommodate and monitor asymptomatic to moderately symptomatic case-patients who do not require hospital admission.

NCT ID: NCT04625218 Suspended - COVID-19 Pneumonia Clinical Trials

Hydroxychloroquine for the Treatment of SARS-CoV2 (COVID 19) : Pharmacokinetic Study

Start date: January 2022
Study type: Observational

This study is a prospective, observational, open, monocentric multisite, pharmacokinetic study of hydroxychloroquine in critically ill patients. The aim of this study is to assess the pharmacokinetic behavior of hydroxychloroquine in COVID-19 critically ill patients treated with crushed hydroxychloroquine tablets (administered enterally using a nasogastric tube).

NCT ID: NCT04602884 Suspended - Covid19 Clinical Trials

Early Detection of COVID-19 Using Breath Analysis

Start date: September 22, 2020
Phase: N/A
Study type: Interventional


NCT ID: NCT04510038 Suspended - Covid19 Clinical Trials

Colchicine vs Current Standard of Care in Hospitalized Patients With COVID-19 and Cardiac Injury

Start date: January 1, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Open-label randomized study comparing the current standard of care treatment of Covid-19 in hospitalized patients with evidence of cardiac injury vs. a group of the same type of patients treated with colchicine plus current standard of care.

NCT ID: NCT04476589 Suspended - Covid19 Clinical Trials

Prognostication of Recovery in Early Disorders of Consciousness After COVID-19

Start date: July 1, 2020
Study type: Observational

The primary aim of this research proposal is to use multimodal metrics (e.g., clinical data and advanced neuroimaging) in the early (i.e., acute hospitalization) phase of recovery from COVID-19-related disorders of consciousness to predict outcome at 3, 6, and 12 months post-hospitalization. We aim to construct an algorithm that synthesizes the results of these metrics to help predict recovery.

NCT ID: NCT04425720 Suspended - COVID Clinical Trials

Use of Remote Monitoring for COVID-19 Patient

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

The central hypothesis motivating this study is that remote patient monitoring (RPM) of infectious disease patients can efficiently facilitate self-isolation. Additionally, RPM can assist in more rapid identification of patients at risk, facilitate detection of patient deterioration, and enable early interventions, all of which play a vital role in resource utilization and outcomes.

NCT ID: NCT04415073 Suspended - COVID Clinical Trials

A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19

Start date: May 30, 2020
Phase: Phase 2
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care, compared with placebo plus standard of care, in patients with respiratory signs and symptoms secondary to novel coronavirus disease (COVID-19).